Intrommune Therapeutics Announces Grant of European Patent Covering Oral Mucosal Immunotherapy for Food Allergy
08 mars 2019 10h01 HE
|
Intrommune Therapeutics
New York, March 08, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is...
Intrommune Therapeutics Announces First Close of Series A Preferred Equity Financing and Successful Close of Crowdfunding Financing Campaign to Support New Peanut Allergy Treatment
08 nov. 2018 16h44 HE
|
Intrommune Therapeutics
New York, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is...
Intrommune Therapeutics Completes Pre-IND Meeting With FDA on INT301 for Peanut Allergy
06 sept. 2018 07h11 HE
|
Intrommune Therapeutics
New York, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biopharmaceutical company developing a patient-friendly immunotherapy platform for the treatment of food...
Intrommune Therapeutics Submits Pre-IND Meeting Request to the U.S. FDA for INT301, Its Peanut Allergy Oral Mucosal Immunotherapy Drug Candidate, During Food Allergy Awareness Week
15 mai 2018 12h00 HE
|
Intrommune Therapeutics
New York, May 15, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a NYC-based biopharmaceutical company developing a patient-friendly immunotherapy platform for the treatment of food...
Intrommune Therapeutics Announces Crowdfunding Financing Campaign to Support Food Allergy Treatment Research
09 mai 2018 10h36 HE
|
Intrommune Therapeutics
New York, May 09, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics is pleased to announce the launch of a crowdfunding campaign on the Netcapital platform. This campaign supports the next steps of...
Intrommune Therapeutics to Present at Eighth Annual BioNJ BioPartnering Conference
24 avr. 2018 09h27 HE
|
Intrommune Therapeutics
New York, April 24, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a biopharmaceutical company developing a patient-friendly platform for the treatment of food allergies, announced today that it...
Intrommune Therapeutics Announces Expansion of Advisory Board with Three Top Food Allergy Experts
14 juin 2016 07h30 HE
|
Intrommune Therapeutics
New York, June 14, 2016 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a specialty biopharmaceutical company developing a patient-friendly platform for the treatment of food allergies, today...
Intrommune Therapeutics to Present at 2016 BIO International Convention
06 juin 2016 07h55 HE
|
Intrommune Therapeutics
New York, June 06, 2016 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a specialty biopharmaceutical company developing a patient-friendly platform for the treatment of food allergies, today...
Intrommune Therapeutics Announces Positive Results of Proof-of-Concept study of Oral Mucosal Immunotherapy (OMIT) Platform for the Treatment of Allergies
25 avr. 2016 09h08 HE
|
Intrommune Therapeutics
Patient-friendly platform treats allergies while a patient brushes their teeth Oral mucosal route of administration demonstrated to be efficacious No gastrointestinal side effects...
Intrommune Therapeutics Announces Issuance of U.S. Patent Covering Oral Mucosal Immunotherapy for Food Allergy
01 mars 2016 07h10 HE
|
Intrommune Therapeutics
New York, March 01, 2016 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a specialty biopharmaceutical company developing a patient-friendly platform for the treatment of food allergies, announced...